Tylenol sales have fallen drastically from 2007 to 2012 due to product recalls and production shutdowns. Now, Johnson and Johnson, which owns the brand, is promoting a re-launch of Tylenol with a new advertising campaign focusing on what pain relief enables, rather than the hindrance of pain. Chris Schmidt, Consumer Health Industry Analyst at Euromonitor, states that although sales of Tylenol in the US fell by almost one billion US dollars since 2007, the brand image hardly suffered at all and Tylenol should be able to climb back to the top three analgesic brands by 2017.

How will the US-Israel-Iran war shape business dynamics beyond the initial shocks? Visit our insights hub at euromonitor.com for free data-driven tools and resources to help you assess risks and plan for longer-term impact.